Dr. Esteva on Therapeutic Developments in HER2+ Breast Cancer

[adace-ad id="3134"]

Francisco Javier Esteva, MD, discusses therapeutic advances for patients with HER2-positive breast cancer.

Francisco Javier Esteva, MD, PhD, chair of breast oncology, Northwell Health Cancer Institute, discusses therapeutic advances for patients with HER2-positive breast cancer.

Historically, patients with HER2-positive breast cancer have a poor outlook, according to Estiva. With the development of drugs such as trastuzumab (Herceptin), pertuzumab (Perjeta), neratinib (Nerlinx), and ado trastuzumab emtancin (T-DM1; Kadsilla), these patients now have significantly improved outcomes. However, it’s important to understand how these factors are sequenced and combined for maximum benefit, Esteva says.

[adace-ad id="3134"]

Esteva explains that incorporating new adjuvant therapy into a treatment plan is important for patients with early-stage and high-risk breast cancer. Esteva concludes that once patients have been identified who do not achieve a complete satisfactory response to this approach, additional treatments can be used to improve outcomes.

.

[adace-ad id="3134"]

[adace-ad id="3134"]

Leave a reply:

Your email address will not be published.

Site Footer

Sliding Sidebar